# A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

> **NCT04604782** · PHASE1,PHASE2 · RECRUITING · sponsor: **GE Healthcare** · enrollment: 54 (estimated)

## Conditions studied

- Myocardial Ischemia
- Coronary Artery Disease

## Interventions

- **DRUG:** Regadenoson

## Key facts

- **NCT ID:** NCT04604782
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04604782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04604782, "A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04604782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*